Negative in Ames, in vitro chromosomal aberration and mouse bone marrow micronucleus assays
“No genotoxic potential was identified in the standard battery of genotoxic toxicology, including in vitro Ames and chromosomal aberration assays, and in vivo bone marrow micronucleus assay in mice (Module 4.2.3.3).”
✓ VerifiedFDA multi-discipline review, p. 52Source ↗
Carcinogenicity
Not conducted (advanced cancer indication, ICH S9)
“No carcinogenicity studies were conducted. These studies were not required for an oncology drug intended for treatment of patients with severe or life-threatening malignancies per ICH S9 guidance.”
✓ VerifiedFDA multi-discipline review, p. 52Source ↗
Reproductive & developmental
Mouse and rabbit EFD: malformations in rabbits at high dose; post-implantation loss and lower fetal weight in mice
“Abnormalities included external, visceral, and skeletal malformations observed in the high dose group.”
✓ VerifiedFDA multi-discipline review, p. 28Source ↗
Safety pharmacology
No hERG effect; no cardiovascular effects in dogs up to 100 mg/kg; no CNS effects in mice up to 300 mg/kg
“Based on findings from non-GLP and GLP assays, sonrotoclax had no effect on the human Ether-a-go-go-Related Gene (hERG) channel in Chinese Hamster Ovary cells. Sonrotoclax had no effect on cardiovascular parameters in dogs after single or repeated doses of up to 100 mg/kg or on central nervous system parameters in mice after repeated doses of up to 300 mg/kg.”
✓ VerifiedFDA multi-discipline review, p. 26Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative